

PRIX GALIEN USA

OCTOBER 26, 2023, NEW YORK CITY

RECOGNIZING INNOVATION THAT IMPROVES THE HUMAN CONDITION



PRE-EVENT & ON-SITE RESOURCES FOR JOURNALISTS

Galien Foundation events are conducted fully on the record, and we welcome and invite members of the media to participate as engaged stakeholders via onsite discussion, as well as via social media, and to report on proceedings and outcomes.

We certainly appreciate coverage of our events, but our priority is to help you explore and uncover today's key issues and connect with the people and diverse organizations we bring together that make the world a healthier place.

To help facilitate your engagement with our speakers and stakeholders, we are delighted to work with you in the lead-up to our 2023 Forum and Ceremony on:

- Arranging interviews with key speakers and stakeholders
- > Reserving private spaces for on-site interviews
- > Sharing our latest programs and speaker lists

> Providing hi-resolutions imagery (including photos of people, spaces, logos, etc.)

KEEP IN TOUCH

Stay up to date on the latest announcement and key dates from the **Galien Foundation's newsletter**

MORE INFORMATION AND PRESS PASS PLEASE CONTACT:

FINN PARTNERS Holmes Report & PR News / Midsize Agency of the Year

> Kara Bradley, Account Supervisor
T: +1 646 213 7243 - kara.bradley@finnpartners.com

> Madison Steilen, Senior Account Executive madison.steilen@finnpartners.com

> Shifra Power, Excelerator Trainee
T: +1 857 207 8045 - shifra.power@finnpartners.com

HELPFUL LINKS

- > The Galien Foundation
- > Prix Galien USA
- > Galien USA Forum
- > Key Opinion Leaders
- > Galien Worldwide Laureates
- > Pro Bono Humanum Award

Sharon Stone at the Galien Golden Jubilee Awards Ceremony (Oct, 27)

 GF the galien foundation

THE GALIEN FOUNDATION FOSTERS, RECOGNIZES AND REWARDS EXCELLENCE IN SCIENTIFIC INNOVATION THAT IMPROVES THE STATE OF HUMAN HEALTH.

Our Mission

P. Roy Vagelos, Prix Galien USA Committee Chair (2012-2017); retired Chairman & CEO, Merck & Co., Inc. was the first recipient of the Pro Bono Humanum Award for his historic decision to donate the drug Mectizan to more than 530 million people in 34 countries to treat and prevent river blindness.

The Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. The Prix Galien was created in 1970 in honor of Galien, the father of medical science and modern pharmacology Worldwide the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

The Prix Galien is more than an award: it is a movement with a mandate to foster, recognize and reward excellence in scientific innovation to improve the state of human health. Building on an unrivaled network of top biomedical scientists including Nobel Laureates in medicine, the Prix Galien manages an independent, cross-functional and geographically diverse program of events and sponsorships to brand "the best of the best" in new medicines and diagnostics. Our scope is global, and our commitment to progress in medicine is both measurable and concrete. Our members express this through the establishment of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance, academic research and the media.

In addition to recognizing advances in promising therapies, the Prix Galien's annual <u>Roy Vagelos</u> <u>Pro Bono Humanum Award</u> for humanitarian achievements brings a unique focus to the intersection between science, business and politics. The outcome we seek is guided by the synthesis principle that underpins the conduct of science itself: successful innovation where financing, physical assets, knowledge and skills are combined from many sources to move new ideas quickly "from the bench to the bedside," on behalf of patients everywhere.

A TRULY GLOBAL PROGRAM PRESENT IN 15 COUNTRIES*

Our program includes a review of contributions from a new generation of innovators representing diverse sectors in health. Our mission is to advance cross-cultural contacts and harmonize regulation, internal business processes, new information technologies and public-private partnerships to remove barriers to the commercialization of good medicines and expand across to these benefits to all who need them.

* Africa, Belgium, Canada, China, France, Germany, Greece, India, Italy, Netherlands, Poland, Russia, Spain, Switzerland, United Kingdom and the United States.



(*l-r*] Elie Wiesel, Peace Nobel Laureate; Ban Ki-moon, General Secretary, United Nations; Bill Clinton & Philippe Douste-Blazy, 2010 Prix Galien Pro Bono Humanum Award Laureate



THE MEDAL BY ALBERT DE JAEGER

he Prix Galien medal was designed by Albert de Jaeger [1908 – 1992], laureate of the Premier Grand Prix de Rome architectural prize. De Jaeger designed medals for prominent figures such as Pope Pius XII (at the Villa Medicis, 1937) and Pope Jean-Paul I, Presidents Dwight D. Eisenhower and John F. Kennedy, distinguished military leaders including Marshals Leclerc, Koenig, Montgomery, Marshall and Joukov; the Weizmann Institute, as well as numerous artists, literary figures and prominent personalities such as Sacha Guitry, Marcel Proust, Henri de Montherlant, Paul Harris, a number of Nobel Prize laureates, the Empress of Iran SA Farah Diba, Princess Grace of Monaco, and others...

De Jaeger is also the architect of numerous outstanding monuments in France and throughout the world.

The Prix Galien Golden Jubilee:

2022 was a landmark year celebrating 50 years of progress in recognizing excellence in biopharmaceutical and med tech innovations to improve the human condition. As a special feature, our 50th Golden Jubilee year honored the "global best of the very best" in: A- Pharmaceutical; B- Biotechnology; C- Orphan and Rare diseases; D- Vaccines; and E-Medical technology products. Eligibility were drawn from the 250 products awarded the Prix Galien by our 14 member-country chapters between 1970 and 2019, developed by more than 80 innovative companies, most of whom continue to bring new therapies for today's patients with unmet medical needs.

The Galien Forum and Prix Galien USA Ceremony took place on **October 27 in New York City** at the Alexandria Center for Life Science and Museum of Natural History, respectively. During the Ceremony, we also announced **the laureates** for the "Awards of the Jubilee" – which will be selected by all past and present Committee members across the globe.

The Golden Jubilee Short list was announced on December 11, 2021 in Dakar in the presence of the President of the Senegalese Republic, H.E. Macky Sall, alongside many African heads of state and ministers of health and/or environment, the WHO Director-General as well as hundreds of scientists and industry and innovation leaders.

Under the sponsorship of the government of Senegal and the WHO Regional Office for Africa, the Prix Galien

Africa is our first truly region-wide initiative. It stands as a living tribute to the vision of Foundation co-founder, 1986 Nobel peace laureate Elie Wiesel, who believed in medical innovation not only as an industrial policy asset but as a source of social progress, where private enterprise and public engagement combine to deliver a greater public good - health equity and access for all. The best locale to pursue our mission is the African continent, whose young population is destined to double to 2.5 billion people by 2050. According to the World Economic Forum, early-stage entrepreneurial activity is nearly 15% higher in Africa than the global average – yet while the continent is today home to 11% of the world's population, it accounts for a mere 1% of total health spending and carries a crippling 25% of the global disease burden. Taken together, these statistics reveal the progress inherent in what a few years will be the world's youngest and potentially most productive population, but whose prospects depend on more investment in health care as the key driver of development.

Our diverse geographic reach is evident with the International Prix Galien Awards, which launched in 1990, and is conducted every two years to highlight the "best of the best" in research that brings dividends to patients across geographies with differing health needs. This desire to make biopharmaceutical and med tech innovation a global endeavor, bringing progress to patients in all corners of the world, will now be a key priority for the Prix Galien community going forward. We invite all communities with a commitment to the conduct and promotion of life sciences innovation to contribute to this important work.





"Knowledge without conscience is but the ruin of the soul.

- Rabelais - Pantagruel, 1532

"The mission of The Galien Foundation is to be the premiere platform where humanitarians and innovators at the forefront of biomedical research gather annually to honor highest achievement."

Bruno Cohen Galien Foundation Chairman

Prix Galien USA FOUNDING COMMITTEE 2007-2011



"Thanks to their gifts to society and their determination to alleviate and cure its woes, the scientists deserve to be ranked among the true friends of the human race."

Pr Elie Wiesel Peace Nobel Laureate - Boston University

* Honorary Founding President In Memoriam The Galien Foundation



Michael S. Brown, MD Nobel Laureate Professor of Molecular Genetics and Internal Medicine UT Southwestern Medical Center at Dallas



Barry S. Coller, MD Vice President for M edical Affairs and Physician-in-Chief, Rockefeller University



Eric R. Kandel, MD Nobel Laureate Professor of physiology and Cellular Biophysics Columbia University



Bengt Samuelsson, MD, PhD Nobel Laureate

Nobel Laureate Professor, Karolinska Institutet; Former President Karolinska Institutet; Former Chairman Nobel Foundation



Walter Gilbert, PhD Nobel Laureate Professor Emeritus Harvard University



Joshua Lederberg, MD, PhD Nobel Laureate Professor Emeritus, Laboratory of Molecular Genetics and Informatics, Rockefeller University



Jan T. Vilcek, MD Professor of Microbiology New York University School of Medicine



Joseph Gooldstein, MD Nobel Laureate Professor of Molecular Genetics and Internal Medicine UT, Southwestern Medical Center at Dallas



Richard A. Lerner, MD Professor of Immunochemistry, Chair in Chemistry Scripps Research Institute



Gerald Weissmann, MD Professor of Rheumatology and Director of Biotechnology Study Center New York University School of Medicine





Paul Greengard, PhD Nobel Laureate Professor of Molecular and Cellular Neuroscience Rockefeller University



Paul A. Marks, MD Laboratory Head of Cell Biology Memorial Sloan Kettering Cancer Center

A RECORD OF LEADERSHIP IN BRINGING THE BEST OF BIOMEDICAL DISCOVERY TO THE ATTENTION OF THE WORLD



"The Prix Galien is a welcome initiative to stimulate creative research and promote excellence."

Barack Obama American President - 2008



"I am particularly grateful to receive this award and I will treasure it"

Bill Clinton American President - 2010



"The Prix Galien honors outstanding achievement in two areas that are critical to human health: science and innovation."

Tedros Adhanom Ghebreyesus

Director-General, World Health Organization - 2018



"I know the importance of the Prix Galien which rewards every year therapeutic innovations and research works among the most creative."

Emmanuel Macron French President - 2018



"The Prix Galien Awards are a true celebration of the years of hard work that are required to produce lifechanging interventions."

Bill & Melinda Gates



"Prix Galien recognizes men and women from the pharmaceutical and biomedical industries whose contributions of science have improved and saved countless lives."

Michael Bloomberg Mayor of the City of New York - 2010



"We recognize the importance of the Prix Galien in promoting drug research, and we salute the excellent work of the Jury."

Philippe Douste-Blazy French Minister of Foreign Affairs – 2006



"The Galien Foundation, created to honor and catalyze excellence in scientific innovation, recognizes outstanding achievement with the prestigious Prix Galien Award."

Bill De Blasio Mayor of the City of New York - 2015



"I applaud Prix Galien for recognizing the pioneering spirit of America innovation and research."

John McCain American Senator - 2008



"The Prix Galien since 1970 is dedicated to promoting the research and development of the medicine and medicine industries."

Macky Sall Senegalese President - 2018



"I welcome you to the annual Prix Galien awards for innovative excellence in biomedical products and health technologies. The awards are among the highest honors in science and commerce."

Jimmy Carter American President - 2017



"It is a pleasure to congratulate all those who promote the Prix Galien and pharmaceutical research: they play a vital role in the fight against disease throughout the world."

John Major British Prime Minister - 1996



"The Prix Galien is the right event, on the right issue at the right time. I thank the Galien Foundation for bringing us together and for recognizing that a healthier world is a safer world and a more just world."

BAN Ki-moon UN Secretary-General - 2010



"The Prix Galien is a prestigious award, a magnificent occasion to pay recognition to our researchers and to encourage our industry."

Jean Chretien Canadian Prime Minister -1994



"When Olympic rhymes with Galenic: there is a gold medal that can be won for an extraordinary achievement: this is the Galien Award, the Oscar of pharmaceutical research."

Walter Sutter

Swiss State Advisor, Director of the Public Economy - 2004



"The Prix Galien USA recognizes the important research necessary to develop innovative medicines and devices that have a life-saving impact on individuals and families across the globe."

Kathleen Sebelius

American Secretary of Health and Human Services - 2011



"I'd also like to congratulate all the candidates for the 5th Annual Prix Galien Awards Competition, which honors those in the pharmaceutical industry who have developed the technical, scientific and clinical research skills necessary to develop innovative medicines and devices. Your work is invaluable."

Margaret A. Hamburg, M.D.

Commissioner of Food and Drugs US Food and Drug Administration - 2011





8



"It's one thing to make a movie... it's another to save people's lives. Very very proud to be here and witness this."

Sharone Stone

What were the greatest achievements with positive impact on human health over 50 years from among Prix Galien Winning Innovations?

GALIEN'S BEST-OF-THE-BEST FROM THE HALF CENTURY 1970-2020

	GOLD MEDAL	SILVER MEDAL	BRONZE MEDAL
BEST BIOTECHNOLOGY PRODUCT	ROCHE / GENENTECH Herceptin (trastuzumab)	MERCK & CO., INC KEYTRUDA® (pembrolizumab)	ABBVIE HUMIRA® (adalimumab)
BEST PHARMACEUTICAL PRODUCT	NOVARTIS PHARMACEUTICALS CORPORATION GLEEVEC® (imatinib mesylate)	MERCK & CO., INC ZOCOR® (simvastatin)	GLAXOSMITHKLINE AUGMENTIN (amoxicillin/clavulanate potassium)
BEST MEDICAL TECHNOLOGY	ABBOTT FreeStyle® Libre 14 Day Flash Glucose Monitoring System	EDWARDS LIFESCIENCES Edwards SAPIEN 3 Ultra™ transcatheter heart valve system	ROCHE DIAGNOSTICS cobas® HPV test
BEST ORPHAN/ RARE DISEASE PRODUCT	NOVARTIS PHARMACEUTICALS CORPORATION Kymriah®	BIOGEN/IONIS SPINRAZA® (nusinersen)	VERTEX PHARMACEUTICALS KALYDECO® (ivacaftor)
BEST VACCINE	MERCK & CO., INC GARDASIL® & GARDASIL® 9	PFIZER PREVNAR 13	SANOFI PASTEUR MSD Vaxelis 6-in-1 Infant Vaccine



PRIX GALIEN USA AWARD WINNERS SHARE...



"What an amazing recognition for our global team, who have spent decades developing and distributing this vaccine. Congratulations."

Albert Bourla Chairman and CEO, Pfizer



"Merck's mission is to translate science into medically important products that positively impact humanity, so it is natural for us to support the Prix Galien, since it supports exactly that."

Kenneth C. Frazier Chaiman, CEO and President, Merck



"The Galien Foundation brings together the top scientists in the world. You have Nobel Laureates across the spectrum of scientific disciplines meeting and talking with members of the pharmaceutical industry to see what's going on at the cutting edge, because ultimately that's going to benefit patients."

William Hait, MD, PhD

Global Head, Research & Development Janssen, Pharmaceutical Companies of Johnson & Johnson



"The launch of Prix Galien India is a meaningful tribute to India's contributions to science and medicine, and to the ways India's talent and ingenuity strengthen our shared work of forging a healthier future for all."

Vas Narasimhan, MD CEO, Novartis





PRIX GALIEN USA CEREMONY 2023

DIGITAL GALIEN WEEK OF INNOVATION OCTOBER 23 - 25

The Galien Week of Innovation presents an exclusive series of thematic webinars featuring nominees of the Prix Galien USA Awards discussing the topics on everyone's minds through the lens of the life-changing innovations they have successfully brought to market. GALIEN AWARDS CEREMONY OCTOBER 26, 2023 - 6:30 PM AMERICAN MUSEUM OF NATURAL HISTORY NEW YORK CITY

SUBMIT YOUR INNOVATION



Our annual gala awards dinner is a creative recognition of the productive and positive power of partnerships that drive progress in medical science. It is peer exchange with a public purpose - with a diverse range of opportunities for contact with a range of interests, from professional and scientific groups, academia and governments to patient associations, other nonprofit organizations and the media.

FOR MORE INFORMATION

Elsa Rive T. 347 654 9526 elsa@galienfoundation.org

Laetitia Parienti T. 212 685 1592 Iparienti@galienfoundation.org

Robin Welbers T. 917 781 0521 robin@galienfoundation.org

PRIX GALIEN USA COMMITTEES 2023

CATEGORIES

Best Medical Technology Best Digital Health Best Incubator/Accelerator/Equity Best StartUp



Bernard POUSSOT Committee Chair Director, Roche Holding, Former Chairman & CEO, Wyeth



Roch DOLIVEUX Honorary CEO, UCB



Mikael DOLSTEN Global R&D President, Pfizer



Alex GORSKY Former Executive Chairman, Johnson & Johnson



Penny HEATON Global Therapeutic Area Head, Vaccines, Janssen



François MAISONROUGE Senior Managing Director, Evercore Partners



Joel S. MARCUS Executive Chairman & Founder, Alexandria



Sheri McCOY Board of Directors, AstraZeneca, Former CEO, Avon



Elias ZERHOUNI Former Head of Global R&D, Sanofi

This Prix Galien Committee is supported by two subcommittees and two advisory boards (pgs 14-15).

CATEGORIES

Best Pharmaceutical Product Best Biotechnology Product Best Product for Rare/Orphan Diseases



Michael ROSENBLATT, MD Committee Chair



Linda B. BUCK, PhD Nobel Laureate Fred Hutchinson Cancer Research Center member, and Professor of Physiology and Biophysics, University of Washington



Susan DESMOND-HELLMANN, MD, MPh Former Chief Executive Officer, Bill & Melinda Gates Foundation



Laurie GLIMCHER, MD President and CEO, Dana Farber Cancer Institute; Professor of Medicine, Harvard Medical School

13



Mary-Claire KING, PhD American Cancer Society Professor of Genome Sciences and Medical Genetics, University of Washington



Robert S. LANGER David H. Koch Institute Professor, Massachusetts Institute of Technology



Cato T. LAURENCIN, MD, PhD University Professor, University of Connecticut



Steven LESTER, MD Chief Medical Officer, Mayo Clinic-ASU MedTech Accelerator



Stanley B. PRUSINER, MD Nobel Laureate Professor of Neurology Director, Institute for Neurodegenerative Diseases, University of California, San Francisco



Pr Phillip A. SHARP, PhD Nobel Laureate Professor of Biology and member of the Koch Institute, Chair of the advisory board of the MIT Jameel Clinic



Marc TESSIER-LAVIGNE, PhD President, Stanford University



P. Roy VAGELOS Committee Chair 2012-2017

Retired Chairman & CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals, Inc.

During the ceremony we will bestow the Roy Vagelos Pro Bono Humanum Award for Global Health Equity



Prix Galien USA subcommittees and advisory boards prescreen submitted innovations in the categories Best Medical Technology, Best Incubator/Accelerator/Equity, Best Digital Health and Best StartUp. A short list of recommendations in each of these categories is presented to the Prix Galien USA committee for Judging.

SUB-COMMITTEE MEDICAL TECHNOLOGY



14

Lisa EARNHARDT Executive Vice President, Medical Device, Abbott



Robert S. LANGER David H. Koch Institute Professor, Massachusetts Institute of Technology



Cato T. LAURENCIN, MD, PhD University Professor, University of Connecticut



Steven LESTER, MD Chief Medical Officer, Mayo Clinic-ASU MedTech Accelerator



Michel PAIRET Head of Innovation Unit – Board of Managing Directors, Boehringer Ingelheim

SUB-COMMITTEE INCUBATOR, ACCELERATOR, EQUITY



Gil BASHE Chair Global Health and Purpose, Finn Partners



Michelle LONGMIRE, MD Co-Founder & CEO, Medable Inc.



Ron COHEN, MD Founder, President & CEO, Acorda Therapeutics



Cheryl PEGUS, MD Executive Vice President of Health & Wellness, Walmart



Jamey EDWARDS Former CEO, Emergent Medical Associates



James PRUTOW, JD, MBA Advisory Partner – Life Sciences, Molecular Diagnostics, Global Healthcare, PwC Consulting



Amir KALALI, MD Chairman & Chief Curator CNS Summit/Co-Chair Decentralized Trial Research, Alliance

ADVISORY BOARD DIGITAL HEALTH



Junaid BAJWA Chief Medical Scientist, Microsoft Research, Microsoft



Jay RAJDA, MD Clinical Leader, Healthcare, Amazon



Chemu LANG'AT Chief Operating Officer, Best Buy Health



MaryAnne RIZK, PhD Chief Strategy Officer Medable Inc.



Joseph MOSCOLA Executive Vice President, Head, Industry, Enterprises Services, Nothwell Health



Steven ROSENBERG Chief Executive Officer, uMotif



Sachin NANAVATI Healthcare, Google



Daniel VIAL Former Advisor of Sanofi CEO, Healthcare Consultant

15

ADVISORY BOARD STARTUP



Gaye BOK, PhD Partner, AI and Digital Innovation Fund, Mass General Brigham



Michael LANGER Expert





Christine **BRENNAN, PhD** Managing Director, Vertex Venture HC



Detlev MENNERICH Corporate SVP, Global Head of Business Development & Licensing (BD&L), Boehringer Ingelheim



Dennis PURCELL Founder and Senior Advisor -Aisling Capital



Luba GREENWOOD Managing Partner, Dana Farber Cancer Institute Venture Fund



GF THE GALIEN FOUNDATION

Rodolphe KATRA, PhD Sr. Research Director & Technical Fellow, Medtronic



Amir NAIBERG Ass. Vice Chancellor Technology Development Group, UCLA



Uciane SCARLETT, PhD Partner, MPM Capital



Leighanne OH, MS Life Sciences Investor - Novo





Emerging Science & Innovation,

Partnering Pfizer



PRIX GALIEN USA WINNERS 2007 - PRESENT

2022

Best Pharmaceutical Product LUMAKRAS® - Amgen Inc.

Best Biotechnology Product Inmazeb[™] (atoltivimab, maftivimab, and odesivimabebgn) - Regeneron Pharmaceuticals, Inc.

Best Medical Technology Cala Trio™ - Cala Health

Best Digital Health Solution Exscientia's end-to-end Al-driven precision medicine platform, Exscientia

16

Best Incubator/Accelerator/ Equity BioLabs / LabCentral

Best Startup

Pharma/Biotech: Aurion Biotech Medtech: Quantum Surgical Digital Health: Akili Interactive

Pro Bono Humanum Award Stanley T. Crooke

2021

Best Pharmaceutical Product Entresto[®], Novartis Pharmaceuticals Corp.

Best Biotechnology Product OXBRYTA®, Global Blood Therapeutics, Inc.

Best Medical Technology AcrySof® IQ PanOptix® Trifocal Intraocular Lens, ALCON

Best Digital Health Product Huma Therapeutics' Remote Patient Monitoring Platform, Huma

Pro Bono Humanum Award Stephane Bancel, Albert Bourla, Alex Gorsky, Daniel M. Skovronsky, Pascal Soriot, George D. Yancopoulos

2020

Best Pharmaceutical Product Pretomanid, TB Alliance

Best Biotechnology Product

Tegsedi®, Akcea Therapeutics & Ionis Pharmaceuticals; ONPATTRO®, Alnylam Pharmaceuticals; VYNDAQEL®, Pfizer Inc. Best Medical Technology Abbott's MitraClip™ Transcatheter Mitral Valve Repair System, Abbott

Best Digital Health Product SOMRYST, Pear Therapeutics

Pro Bono Humanum Award Dr William H. Foege

2019

Best Pharmaceutical Product SHINGRIX, GlaxoSmithKline

Best Biotechnology Product LUXTURNA[™], Spark Therapeutics

Best Medical Technology FreeStyle® Libre 14 Day Flash Glucose Monitoring System, Abbott

Pro Bono Humanum Award Jim and Marilyn Simons, The Simons Foundation

2018

Best Pharmaceutical Product IDHIFA®, Celgene Agios

Best Biotechnology Product Yescarta®, Kite, a Gilead Company & Kymriah®, Novartis Pharmaceuticals Corporation

Best Medical Technology WATCHMANTM, Boston Scientific Corporation

Pro Bono Humanum Award Bill and Melinda Gates, Co-Chairs, Bill & Melinda Gates Foundation

2017

Best Pharmaceutical Product Venclexta™, AbbVie & Genentech (a Member of the Roche Group

Best Biotechnology Product SPINRAZA®, Biogen & Ionis Pharmaceuticals

Best Medical Technology Exablate Neuro, INSIGHTEC

Pro Bono Humanum Award Former President Jimmy Carter

2016

Best Pharmaceutical Agent Ibrance®, Pfizer, Inc.

Best Biotechnology Product Cosentyx®, Novartis

Best Medical Technology Cologuard®, Exact Sciences

Pro Bono Humanum Award Paula S. Apsell

2015

Best Pharmaceutical Agent IMBRUVICA®, Janssen Biotech, Inc. & Pharmacyclics LLC, an AbbVie Company

Best Biotechnology Product OPDIVO®, Bristol-Myers Squibb KEYTRUDA®, Merck & Co., Inc.

Best Medical Technology T2Candida Panel, T2 Biosystems, Inc.

Pro Bono Humanum Award Pr Mary-Claire King

DISCOVERY OF THE DECADE

Best Pharmaceutical Agent Gleevec®, Novartis

Best Biotechnology Product Yervoy®, Bristol-Myers Squibb

Best Medical Technology Sapien 3TM, Edwards Lifesciences

2014

Best Pharmaceutical Agent Sovaldi[®] - Gilead Sciences

Best Biotechnology Product HEMACORD[®] - The New York Blood Center's Howard P. Milstein Cord Blood Center

Best Medical Technology Trevo ProVue® - Stryker

Pro Bono Humanum Award Dr Bernard Kouchner

2013

Best Pharmaceutical Agents Zelboraf® - Genentech Best Biotechnology Product Zostavax® - Merck & Co., Inc.

Best Medical Technology S-ICD® System - Boston Scientific

Pro Bono Humanum Award Dr Anthony S. Fauci

2012

Best Pharmaceutical Agents Victrelis® - Merck & Co., Inc.; Incivek® - Vertex Pharmaceuticals

Best Biotechnology Product Yervoy® - Bristol-Myers Squibb

Best Medical Technology Sapien® - Edwards Lifesciences Melody® - Medtronic

Pro Bono Humanum Award Dr Francis S. Collins

2011

Best Pharmaceutical Agent Prevnar13® - Pfizer

Best Biotechnology Product Stelara® - Janssen Prolia and XGEVA® - Amgen

Pro Bono Humanum Award Paul Farmer

2010

Best Pharmaceutical Agent Coartem® - Novartis

Best Biotechnology Product RotaTeq[®] - Merck & Co., Inc.

Best Medical Technology xTAG[®] - Luminex Corporation

Pro Bono Humanum Award Bill Clinton and Philippe Douste-Blazy

2009

Best Pharmaceutical Agent Gleevec® - Novartis

Best Biotechnology Product Nplate® - Amgen; Promacta® - GlaxoSmithKline

Best Medical Technology Cellsearch® - Veridex (J&J)

Pro Bono Humanum Award Jeffrey Sachs and Barry Bloom

2008

Best Pharmaceutical Agent Isentress® - Merck & Co., Inc.; Selzentry® - Pfizer

Best Biotechnology Product Soliris® - Alexion; Infuse® -Wyeth

Special therapeutic development Revlimid® - Celgene

Pro Bono Humanum Award Sheldon Segal

2007

Best Pharmaceutical Agent Januvia[®] - Merck & Co., Inc.; Chantix[®] - Pfizer

Best Biotechnology Product Humira® - Abbott; Gardasil® - Merck & Co., Inc.

Pro Bono Humanum Award Dr Roy Vagelos



AROUND THE WORLD, PRIX GALIEN HAS AN UNRIVALED REPUTATION FOR INTELLECTUAL RIGOR AND INTEGRITY...

AFRICA, BELGIUM, CANADA, CHINA, FRANCE, GERMANY, GREECE, ITALY, NETHERLANDS, POLAND, RUSSIA, SPAIN, SWITZERLAND, UNITED KINGDOM, UNITED STATES.





PRIX GALIEN INTERNATIONAL **2024**



The Prix Galien International Awards is organized every two years. The International Committee is composed of Committee chairs from member nations.

All approved innovations that have been granted a national Prix Galien during the preceding two years are eligible.

PRIX GALIEN INTERNATIONAL CHARTER

The Prix Galien International Awards for Life Science Research is organized every two years.

The Prix Galien International Committee is composed of chairs from the member nations.

Are eligible to compete in the Prix Galien International all marketed drugs, medical devices and digital solutions that have been granted a national Prix Galien.

The Prix Galien International ceremony will take place in a city chosen by the Galien Foundation Board .

Entries must be submitted in English online at <u>www.galienfoundation.org</u>

1990	PARIS, FRANCE
1992	BRUSSELS, BELGIUM
1994	BERLIN, GERMANY
1996	LONDON, UK
1998	PARIS, FRANCE
2000	MONTREAL, CANADA
2002	MADRID, SPAIN
2004	LISBON, PORTUGAL
2006	ZURICH, SWITZERLAND
2008	BERLIN, GERMANY
2010	NEW YORK, USA
2012	LYON, FRANCE
2014	MONACO
2016	PARIS, FRANCE
2018	DAKAR, SÉNÉGAL
2020	POSTPONED DUE TO
	COVID-19 PANDEMIC
2022	LONDON
2024	ROMA

PRO BONO HUMANUM LAUREATES SINCE 2007

Presented at the Ceremony, the Pro Bono Humanum Award recognizes exemplary and innovative efforts in improving the human condition. This special award was presented by the late and beloved Elie Wiesel, in presence of the Prix Galien USA Committee. The Pro Bono Humanum Award was renamed the Roy Vagelos Pro Bono Humanum Award in 2017 in recognition of his decades of leadership in improving the state of human health through medicines innovation.





2022

Stanley Crooke

Dr. Crooke is recognized for being among he first in industry to make a commitment o open science a key element of the modern R&D enterprise and to embrace the principle hat even patients with the rarest of afflictions deserve the best talent and expertise our R&D ndustry can offer.



20

2021

Stephane Bancel CEO Moderna

Alex Gorsky Chairman, Board of Directors & CEO Johnson & Johnson

Pascal Soriot CEO **Albert Bourla** Chairman & CE(Pfizer

David Ricks Chairman & CEC Eli Lilly & Co.

George D. Yancopoulos Co-Founder, President & Chief Scientific Officer For their accomplishments in converting basic science into new preventive vaccines and novel treatment therapeutics to combat the COVID-19 virus. The award highlights the success of these companies in partnering to speed novel vaccines and antibody drug combination to emergency use candidates to regulatory approval and distribution, resulting in the timely mitigation of a pandemic that has caused immense economic damage and human suffering worldwide. All told, we believe the innovative medicines industry has done more in partnership to defeat the pandemic than any other institution, public or private. This is a record that deserves recognition, which is precisely the Galien community's global mission



2019

Jim and Marilyn Simons The Simons Foundation

In recognition of their proactive support of basic scientific research undertaken in the pursuit of understanding the phenomena of our world, often including research by scientists in the early

stages of their careers, a new collaborative funding model to facilitate cross-disciplinary breakthroughs, and efforts to inspire emerging and current philanthropists to dedicate a portion of their philanthropy to basic science.



2017

Jimmy Carter Former U.S. President & Co-Founder, The Carter Cent

For playing a leadership role in the elimination of river blindness in four of the six Latin American countries

and halting the disease's transmission in several locations in Africa where more than 99 percent of the global cases exist.



2020

Dr. William H. Foege

In recognition of this role in building the global strategy that resulted in the eradication of this smallpox virus in 1980, a success that helped foster higher rates of immunization against many other infectious and communicable diseases throughout the developing world.



2018

Bill and Melinda Gates Bill & Melinda Gates Foundation

In recognition of their extraordinary work championing scientific and technological innovation to improve life for the world's poorest people.

As co-chairs of the Bill & Melinda Gates Foundation, they have catalyzed unprecedented progress in global health, poverty reduction, and public education in the U.S.



2016

Paula S. Apsell

For turning great science into a human society's first line of defense against

further progress in human health.



2014

Dr. Bernard Kouchner

Co-Founder, Doctors Without Border &

both legitimacy and worldwide acclaim and for his fieldwork



2012

Dr. Francis S. Collins



2010

Bill Clinton and Philippe Douste-Blazy



2008

Sheldon Segal and the Population Council



2007

P. Roy Vagelos

For the River Blindness Program and



2015

Pr. Mary-Claire King



2013

Dr. Anthony Fauci



2011



2009

Barry Bloom and Jeffrev Sachs

Harvard Professor Barry Bloom for

bringing the fruits of basic biological science to those who

Pr. Paul Farmer



Former Congressman Patrick J. KENNEDY, Founder, The Kennedy Forum

GALIEN FORUM

GALIEN FORUM OCTOBER 26, 2023 - 7:30 AM ALEXANDRIA CENTER FOR LIFE SCIENCE NEW YORK CITY

The Galien Forum, held every autumn at New York's Alexandria Center for Life Sciences since 2010, offers a full day of dynamic presentations and spirited discussions with top scientists and industry researchers who offer perspectives on the most significant challenges in the global burden of disease and highlights the latest research and clinical pathways toward diagnosis, treatment, and cure.

Our 900 attendees represent the top executive and thought leadership from academic research, industry, government, the regulatory community, patient organizations, international organizations, and the media. Time and again, Forum participants praise the caliber of the speakers and their fellow attendees, the quality of the panel discussions and presentations, and the recognition of industry's critical role in creating life-saving innovations.

These events represent peer-to-peer exchange with a public purpose, featuring unique opportunities to connect with a diverse range of people, organizations and interests from professional and scientific groups, academia, governmental organizations and patient associations, non-profit organizations and the media.



Cancer Immunotherapeutics

The Brain Initiative

Personalized Medicine's Impact on Drug R&D and Patient Care

Improving Efficiency in Drug Development

What is "Value" and How Can it be Measured and Demonstrated in Therapeutic Innovations?

U.S. Health Reform

A New Agenda for Global Health

The Future of Digital Health and its Impact on Healthcare

New Mechanisms for Industry-Academia Collaboration

The Future of Targeted Drug Delivery

Microbiota in Human Disease

Autism - The Next Decade

Untangling the Web of Neurodegeneration

Precision Medicine: Delivering on the Promise Molecular Scissors: What Can We Expect from Gene Editing?

 ${\rm GF}$ the galien foundation



Robert M. CALIFF, Commissioner of Food and Drugs, U.S. Food and Drug Administration

AMONG THE THOUGHT LEADERS WHO HAVE SPOKEN AT THE GALIEN FORUM

Richard AXEL, MD

Nobel Laureate Co-director, Kavli Institute for Brain Science, Columbia University Medical Centre

Stephane BANCEL CEO, Moderna

Michael BLOOMBERG Former Mayor, City of New York

Albert BOURLA Chairman and CEO, Pfizer

Robert BRADWAY Chairman and CEO, Amgen

Michael S. BROWN Nobel Laureate Professor of Molecular Genetics and Internal Medicine, UT Southwestern Medical Center at Dallas

Giovanni CAFORIO *Chairman and CEO*, Bristol Myers Squibb

Robert M. CALIFF *Commissioner of Food and Drugs*, U.S. Food and Drug Administration

Stanley T. CROOKE *Founder and CEO*, n-Lorem Foundation

Pam CHENG Executive Vice-President, Operations and Information Technology, AstraZeneca

Rob DAVIS *CEO and President,* Merck & Co., Inc Mikael DOLSTEN

Chief Scientific Officer and President Worldwide Research, Development and Medical, Pfizer

Ezekiel EMANUEL, MD, PhD

Vice Provost for Global Initiatives; Chair, Dept. of Medical Ethics and Health Policy Levy; University Professor Perelman School of Medicine and The Wharton School, University of Pennsylvania

Anthony S. FAUCI Director, National Institute of Allergy and Infectious Diseases; Chief Advisor to the President of the United States

Jacqualyn FOUSE, PhD *Chief Executive Officer,* Agios

Maria C. FREIRE, PhD President and Executive Director, Foundation for the National Institutes of Health

Laurie GLIMCHER *President and CEO* Dana-Farber Cancer Institute, Richard and

Joseph GOLDSTEIN Nobel Laureate Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center at Dallas

Alex GORSKY *Chairman and CEO*, Johnson & Johnson Paul GREENGARD, PhD Nobel Laureate Professor of Molecular and Cellular Neuroscience, Rockefeller University

Sebastian GUTH *President*, Bayer Pharmaceuticals, Americas Region

William N. HAIT, MD, PhD Global Head, Research and Development, Janssen Research & Development

Kathy A. HIGH President and Head of R&D, Spark Therapeutics

Petra JANTZER Senior Managing Director – Life Sciences, Europe, Accenture

William G. KAELIN Nobel Laureate Sidney Farber Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Eric R. KANDEL, MD Nobel Laureate Professor of Physiology and Cellular Biophysics, Columbia University; Director Bio-technology Study Center, NYU School of Medicine

Ariel KATZ Co-founder and CEO, H1

Patrick J. KENNEDY Former Congressman Founder, The Kennedy Forum John LECHLEITER Chairman and CEO, Eli Lilly & Company

Jeffrey LEIDEN *Chairman, President and CEO*, Vertex

Michelle LONGMIRE *Co-founder and CEO*, Medable

Joel S. MARCUS Chairman, CEO and Founder, Alexandria Real Estate Equities / Alexandria Venture Investments; Co-Founder Alexandria Summit

Michelle Mc HEATH Former President and CEO, BIO

Mark MCCLELLAN, MD, PhD

Director, Duke-Robert J. Margolis Center for Health Policy; Professor of Business, Medicine, and Health Policy, Duke University

Elizabeth NABEL MD *President*, Brigham and Women's Hospital

Richard F. POPS *Chairman and CEO*, Alkermes

Guido RASI Executive Director, European Medicines Agency Bengt SAMUELSSON, MD, PhD Nobel Laureate Former President, Karolinska Institute Former Chairman, Nobel Foundation 23

MARC TESSIER-LAVIGNE, PHD President, Stanford

Eric TOPOL, MD Director and Founder, Scripps Research Translational Institute; Author, Deep Learning

P. Roy VAGELOS, MD Retired Chairman and CEO, Merck & Co., Inc.; Chairman of the Board, Regeneron Pharmaceuticals

Bert VOGELSTEIN Professor, Johns Hopkins Medical School

Christophe WEBER PharmD

Representative Director, President and CEO, Takeda Pharmaceutical Company Limited

George YANCOPOULOS, MD, PhD

Chief Scientific Officer, Regeneron Pharmaceuticals; President, Regeneron Laboratories

Krishna YESHWANT, MD

General Partner, Google Ventures

Elias ZERHOUNI Former President, Global R&D. Sanofi OCTOBER 26, 2023 / AMERICAN MUSEUM OF NATURAL HISTORY, NYC

AND THE 2023 WINNER IS?

The Prix Galien Award

SINCE 1970 regarded as the equivalent	PRIX Galien Hall of Fame		A DAY OF THE PARTY	recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. The Prix Galien was created in 1970 in honor of Galien, the father of medical science and modern pharmacology.
2022 Inmazeb ^M Lumakras® (Cala Tio™ 2022) research. 2021 DXBRYTA* Entresto* AcrySof*) 2021 Huma Platform 2020 Presedi* ONPATTRO* YNDAQEL*) 2020 2020 Pretomanidi AbbottS Mitraclip* 2020 Transcatheter Mitral Valve Repair System 2019 2019 SHINGRIX LUXTURNA™ 2019 FreeStyle* Libre 2018 2017 Exablate Neuro* Spinraza* Venclexta* 2016 2016 Cologuard* Cosentyx* Ibrance* 2016 2015 Imbruvica* Keytruda* Opdivo* T2Candida Panel 2015 2013 S-ICD* System Zlobard* Zostavax* 2013 2013 S-ICD* System Zlobard* Zostavax* 2013 2013 Coivek* Meldoy* Sapien® Victrelis* Yervoy* 2012 2011 Evenari3* Prolia and XGEVA* Stelara* 2011 2010 Coartem* Rotateg* xAG* 2011	SINCE 1970		Kanada and a second sec	Worldwide, the Prix Galien is regarded as the equivalent of the
2021 OXBRYTA® I Entresto® I AcrySof® 2021 Huma Platform 2020 Tegesedi® I ONPATTRO® I VMIDACEL® I 2020 Tegesedi® I ONPATTRO® I VMIDACEL® I 2020 Transcatheter Mitral Valve Repair System I 2019 SHINCRIX I LUXTURNA™I I 2018 IDHIFA® I Vescarta® I Kymriah® I 2018 IDHIFA® I Vescarta® I Kymriah® I 2017 Exablate Neuro® I Spinraza® I Venclexta™ I 2015 Imbruvica® I Keytruda® I Opdivo® I T2Candida Panel 2015 2014 Hemacord™ I Trevo® Provue™ Sovaldi 2014 2013 S-ICD® System I Zelboraf® I Zostavax® 2013 2014 Hemacord™ I Trevo® Provue™ Sovaldi 2014 2013 S-ICD® System I Zelboraf® I Zostavax® 2013 2012 Incivek® I Melody® I Sapien® I Victrelis® Yervoy® 2012 2011 Dervnari3® I Prolia and XCEVA® I Stelara® 2011 2010 Cortem® I Rotateq® I XIAO® 2010		2022	2 Inmazeb™ I Lumakras® I Cala Trio™2022 I BioLabs – Exscientia	Nobel Prize in biopharmaceutical research.
2010 Huma Platform 2020 Tegsedi® I ONPATTRO® I VYNDAQEL®1 Pretomanid I Abbott'S Mitraclip™ 2020 Transcatheter Mitral Valve Repair System I Smryst 2019 SHINCRIX I LUXTURNA™ I 2019 2018 IDHIFA® I Vescarta® I Kymriah® I 2019 2018 2017 Exablate Neuro® I Spinraza® I Venclexta™ 2017 2016 Cologuard® I Cosentyx® I Ibrance® 2016 2015 Irnbruvica® I Keytruda® I Opdivo® I T2Candida Panel 2015 2014 Hemacord™ I Cresentyx® IIbrance® 2014 2013 S-ICD® System I Zeloraf® I Zostavax® 2013 2012 Incivek® I Melody® I Sapien® I Victrelis® Yervoy® 2012 2011 Prevnari3" I Prolia and XGEVA® I Stelara® 2011 2011 Coartem® I Potaleq I XTAG® 2010		1415		
2020 Tegsedi® I ONPATTRO® I VYNDAQEL® 1 Pretomanid I Abbott'S Mitraclip™ 2020 Transcatheter Mitral Valve Repair System 1 Smryst 2019 2019 SHINORIX 1 LUXTURNA™I 2019 PreeStyle® Libre 2018 2018 IDHIFA® I Yescarta® I Kymriah® 1 2018 2017 Exablate Neuro® I Spinraza® I Venclexta™ 2017 2016 Cologuard® I Cosentyx® I Ibrance® 2016 2015 Imbruvica® I Keytruda® I Opdivo® I T2Candida Panel 2015 2014 Hemacord™ I Trevo®Provue™ I Sovaldi® 2014 2013 S-ICD® System I Zeloraf® I Zostavax® 2013 2012 Incivek® I Meldy® I Sapien® I Victrelis® Yervoy® 2012 2011 Prevnart3® I Prolia and XGEVA® I Stelara® 2011 2010 Coartem® I Potateq® I XAG® 2011		2021	OVERTING TENTICISCO TATONSOL T	
2020 Pretomanid I Abbott's Mitraclig™ 2020 Transcatheter Mitral Valve Repair System I Smryst 2019 SHINCRIX I LUXTURNA™ I 2019 2018 IDHIFA [®] I Vescarta [®] I Kymriah [®] I 2018 2017 Exablate Neuro® I Spinraza® I Venclexta [™] 2017 2016 Cologuard® I Cosentyx® I Ibrance® 2016 2015 Imbruvica® I Keytruda® I Opdivo® I T2Candida Panel 2015 2014 Hemacord [™] I Trevo®ProVue [™] I Sovaldi® 2014 2013 S-ICD® System I Zelbora® I Zostavax® 2013 2012 Incivek® I Melody® I Sapien® I Victrelis® Yervoy® 2012 2011 Prevnari3® I Prolia and XGEVA® I Stelara® 2011 2010 Coartem® I Rotateq® I XIAG® 2011				
2019 SHINGRIX I LUXTURNA™) 2019 PreeStyle® Libre 2018 2018 IDHIFA® I Yescarta® I Kymriah® I 2018 2018 IDHIFA® I Yescarta® I Kymriah® I 2018 2017 Exablate Neuro® I Spinraza® I Venclexta™ 2017 2015 Imbruvica® I Keytruda® I Opdivo® I T2Candida Panel 2015 2013 S-ICD® System I Zelbora® I Zostavax® 2013 2012 Incivek® I Melody® I Sapien® I Victrelis® Yervoy® 2012 2011 Prevnar13° I Prolia and XCEVA® I Stelara® 2012 2011 Coartem® I Rotateg® I xIAC® 2012		2020	Pretomanid I Abbott'S Mitraclip™ 202 anscatheter Mitral Valve Repair System I	0
2018 IDHIFA® I Yescarta® I Kymriah® I Watchman™ Left Atrial Appendage Closure Device 2018 2017 Exablate Neuro® I Spinraza® I Venclexta™ 2017 2016 Cologuard® I Cosentyx® I Ibrance® 2016 2015 Imbruvica® I Keytruda® I Opdivo® I T2Candida Panel 2015 2014 Hemacord™ I Trevo® ProVue™ I Sovaldi® 2014 2013 S-ICD® System I Zelbora® I Zostavax® 2013 2012 Incivek® I Melody® I Sapien® I Victrelis® Yervoy® 2012 2011 Prevnar13® I Prolia and XCEVA® I Stelara® 2011 2010 Coartem® I Rotateq® I xTAC® 2011		2019	SHINGRIX I LUXTURNA™ I 2	019
2015 2014Imbruvica® Keytruda® Opdivo® T2Candida Panel 20142015 20142013Hemacord™ Trevo®ProVue™ Sovaldi®20142013S-ICD® System Zelboraf® Zostavax®20132012Incivek® Melody® Sapien® Victrelis® Yervoy®20122011Prevnar13® Prolia and XCEVA® Stelara®20112010Coartem® Rotateg® XTAC®2010		Watch	man™ Left Atrial Appendage Closure Device	
2015 2014Imbruvica® Keytruda® Opdivo® T2Candida Panel 20142015 20142013Hemacord™ Trevo®ProVue™ Sovaldi®20142013S-ICD® System Zelboraf® Zostavax®20132012Incivek® Melody® Sapien® Victrelis® Yervoy®20122011Prevnar13® Prolia and XCEVA® Stelara®20112010Coartem® Rotateg® XTAC®2010				
2015 2014Imbruvica® Keytruda® Opdivo® T2Candida Panel2015 20142014Hemacord™ Trevo®ProVue™ Sovaldi®20142013S-ICD® System Zelboraf® Zostavax®20132012Incivek® Melody® Sapien® Victrelis® Yervoy®20122011PrevnarI3® Prolia and XCEVA® Stelara®20112010Coartem® Rotateg® XTAC®2010		2016	Coloquard® Cosentyx® Ibrance®	2016
2013S-ICD® System Zelboraf® Zostavax®20132012Incivek® Melody® Sapien® Victrelis® Yervoy®20122011Prevnar13® Prolia and XGEVA® Stelara®20112010Coartem® Rotateq® xTAG®2010		2015 Imbri		el 2015
2013 S-ICD® System Zelboraf® Zostavax® 2013 2012 Incivek® Melody® Sapien® Victrelis® Yervoy® 2012 2011 Prevnar13® Prolia and XCEVA® Stelara® 2011 2010 Coartem® Rotateg® xTAC® 2010				
2011 Prevnar13® Prolia and XGEVA® Stelara® 2011 2010 Coartem® Rotateq® xTAG® 2010		2013	S-ICD® System I Zelboraf® I Zostavax®	2013
2010 Coartem® Rotateq® xTAG® 2010	20	012 Inciv	vek® Melody® Sapien [®] Victrelis® Yervoy®	2012
	201	7	Prevnar13 [®] I Prolia and XGEVA [®] I Stelara [®]	2011
2009 Cellsearch® Cleevec® Nplate® Promacta® 2009	2010		Coartem® Rotateq® xTAC®	2010
2008 Infuse® Isentress® Revlimid® Selzentry® Soliris® 2008				
2007 Chantix® Gardasil® Humira® Januvia® 2007	2007	(Chantix® Gardasil® Humira® Januvia® 	2007

THE GALIEN FOUNDATION 99 John Street, Suite 2502 New York, NY 10038 Tel: 212-685-1592

INNOVATORS WIN PRIX GALIEN USA

SUBMIT YOUR INNOVATION